Methods and products for transfecting cells
The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
1. A therapeutic composition, comprising a gene-edited hematopoietic cell, wherein:
the gene-edited hematopoietic cell comprises:
an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, the gene-editing protein comprising a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell; and
a double-strand break in its DNA, the double-strand break being caused by the gene-editing protein and reducing the function of one or more of CCR5 and CXCR4.
2. The therapeutic composition of claim 1 , wherein the gene-editing protein is selected from a TALEN and a zinc finger nuclease.
3. The therapeutic composition of claim 1 , wherein the in vitro transcribed synthetic RNA molecule further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.
4. The therapeutic composition of claim 1 , wherein the double-strand break is within about 5,000,000 bases of the transcription start site of the CCR5 or CXCR4 gene.
5. The therapeutic composition of claim 1 , wherein the hematopoietic cell is a hematopoietic stem cell.
6. The therapeutic composition of claim 1 , wherein the hematopoietic cell is a white blood cell.